Diffuse Large B-cell Lymphoma (ASH 2026) - Sep 26, 2026 - "He will consider where approved treatments such as polatuzumab vedotin in combination with bendamustine-rituximab, loncastuximab tesirine, tafasitamab-lenalidomide, and brentuximab vedotin with lenalidomide-rituximab fit into current management algorithms. He will also discuss promising agents under investigation, including novel therapies targeting B-cell receptor signaling, apoptosis, and lineage-restricted transcription factors. This talk will also review combination strategies being explored to overcome treatment resistance."
B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma
|